Free press releases distribution network?

Agency / Source: Ogilvy Public Relations

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



The GVK BIO Clinical Pharmacology Unit Granted Major Accreditations - The Clinical Pharmacology Unit (CPU) of GVK Biosciences (GVK BIO) received approvals from all major regulatory bodies globally including USFDA, AFSAAPS, WHO and ANVISA
The GVK BIO Clinical Pharmacology Unit Granted Major Accreditations

 

PRZOOM - /newswire/ - Hyderabad, Andhra Pradesh, India, 2008/01/07 - The Clinical Pharmacology Unit (CPU) of GVK Biosciences (GVK BIO) received approvals from all major regulatory bodies globally including USFDA, AFSAAPS, WHO and ANVISA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The approvals open global markets to GVK BIO’s clients in the US, Europe and Latin American countries in addition to the domestic sector.

Manni Kantipudi, President of GVK BIO stated, “The approvals validate GVK BIO’s high quality systems and practices”.

As a first step, GVK BIO has expanded and built a new state-of-the-art Bioanalytical facility in addition to the existing one to cater to the growing business demands. GVK BIO is also setting up its own Clinical Laboratory and aims for an early accreditation.
“GVK BIO aims to be a full service Clinical Research Organization offering services from BA/BE to Phase I through Phase IV Clinical Trials”, said Mr. G.V.Sanjay Reddy, Managing Director, GVK BIO.

Set up in 2001, GVK BIO is a leading CRO in India. GVK BIO started offering Bioavailability/Bioequivalence(BA/BE) services in 2004 and in a very short time received major accreditations from international regulatory authorities such as ANVISA (Brazil) and AFSAAPS (French) and the US FDA. The US FDA has inspected the facilities twice and approved several BA/BE studies conducted by GVK BIO. The BA/BE facility was also inspected and cleared by WHO after a recent audit of one of the studies. GVK BIO’s BA/BE Centre was requalified by ANVISA (Brazilian Regulatory Body) for the third consecutive year.

About Clinical Pharmacology Unit (CPU)
The Clinical Pharmacology Unit (CPU) located at Hyderabad, is one of the largest units in India for Bioavailability and Bioequivalence studies with state-of-the-art infrastructure to cater to global regulatory requirements. The SBU with 144 beds and a comprehensive volunteer database has the capability of undertaking studies for special population and dosage forms like injectables in addition to the conventional studies, which sets it apart from the competition. As of now, CPU has conducted around 300 studies of which more than 50 studies are for USFDA submission.

About GVK BIO

GVK Biosciences, India’s premier Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. The company accelerates the Drug Discovery and Development process of its customers through science and innovation. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai and Gurgaon.

For any further information, please contact:
Sharada Alvakonda
Dy. General Manager – Corporate Communications
GVK Biosciences Private Ltd
Hyderabad
T: +91 40 66929999 - E: sharada[.]gvkbio.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Ogilvy Public Relations

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


The GVK BIO Clinical Pharmacology Unit Granted Major Accreditations

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Sreekar Reddy - Ogilvy.com 
+91 98 66110032 sreekar.reddy[.]ogilvy.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Ogilvy Public Relations securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Ogilvy Public Relations / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Rapid Recovery

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  MagLar, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today